RxDoctor Payments Data

James Ashizawa, MD

Family Medicine · San Juan Capistrano, CANPI 1588654123

Payments from drug & device makers

$1,370in general payments, 2019–2025

Across 20 payments — averaging $68.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$388
  • Bayer$243
  • Boehringer Ingelheim$235
  • Lilly USA, LLC$219
  • Esperion Therapeutics, Inc.$125
  • Kowa Pharmaceuticals America, Inc.$35
  • plus $125 from 5 others

What the payments were for

  • Food & beverage$1,370100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,370 in reported general payments places this provider in the 75th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$39,784
Medicare patients
137
Services billed
765

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide92$98,244
EliquisApixaban81$82,823
MounjaroTirzepatide54$80,451
JanuviaSitagliptin Phosphate58$72,847
JardianceEmpagliflozin39$53,709
XareltoRivaroxaban34$50,256
FarxigaDapagliflozin Propanediol22$37,308
MyrbetriqMirabegron29$24,126
TrulicityDulaglutide19$18,173
MultaqDronedarone Hcl21$16,820
LinzessLinaclotide12$11,639
Icosapent Ethyl23$10,627
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$8,983
Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro17$8,246
LivaloPitavastatin Calcium13$7,590

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$219$98,62473 claims
Novo NordiskOzempic$25$98,24492 claims
PfizerEliquis$15$82,82381 claims
Boehringer IngelheimJardiance$235$53,70939 claims
Kowa Pharmaceuticals America, Inc.Livalo$35$7,59013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 10,533 family medicine providers in California.

Other family medicine in San Juan Capistrano

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →